Blogs
Hot Article
Multiple myeloma is a blood cancer that starts in the plasma cells. Learn about its symptoms, causes, diagnosis, and more in this article.
Case Study: Successful CAR-T Treatment at Shanghai Jiahui
Foreign multiple myeloma patient successfully treated with CAR-T therapy at Shanghai Jiahui International Hospital. Learn more about the cancer treatments.
Case Study: One-Month Remission in High-Risk Myeloma with CAR-T
A case of an ultra-high-risk R/R MM patient who experienced early relapse after autologous stem cell transplant (ASCT) and was successfully treated with CAR-T cells.
Case Study: Equecabtagene & ASCT for Ultra-High-Risk MM
This case outlines treatment using CAR-T Equecabtagene alongside ASCT for a patient with ultra-high-risk multiple myeloma.
Case Study: Equecabtagene for Ultra-High-Risk RRMM
This case study presents the treatment outcomes of Equecabtagene in a patient diagnosed with ultra-high risk multiple myeloma.
Car-T Therapy
Foreign multiple myeloma patient successfully treated with CAR-T therapy at Shanghai Jiahui International Hospital. Learn more about the cancer treatments.
A case of an ultra-high-risk R/R MM patient who experienced early relapse after autologous stem cell transplant (ASCT) and was successfully treated with CAR-T cells.
This case outlines treatment using CAR-T Equecabtagene alongside ASCT for a patient with ultra-high-risk multiple myeloma.
This case study presents the treatment outcomes of Equecabtagene in a patient diagnosed with ultra-high risk multiple myeloma.
This is a case of using BCMA CAR-T to treat RRMM, resulting in hematological complete remission within 22 days after CAR-T reinfusion.
In 2024, the EBMT published the first comparison of four CAR-T treatments for RRMM in China and the US based on MAIC analysis.
Multiple Myeloma
Multiple myeloma is a blood cancer that starts in the plasma cells. Learn about its symptoms, causes, diagnosis, and more in this article.
All Article
Multiple myeloma is a blood cancer that starts in the plasma cells. Learn about its symptoms, causes, diagnosis, and more in this article.
Foreign multiple myeloma patient successfully treated with CAR-T therapy at Shanghai Jiahui International Hospital. Learn more about the cancer treatments.
A case of an ultra-high-risk R/R MM patient who experienced early relapse after autologous stem cell transplant (ASCT) and was successfully treated with CAR-T cells.
This case outlines treatment using CAR-T Equecabtagene alongside ASCT for a patient with ultra-high-risk multiple myeloma.
This case study presents the treatment outcomes of Equecabtagene in a patient diagnosed with ultra-high risk multiple myeloma.
This is a case of using BCMA CAR-T to treat RRMM, resulting in hematological complete remission within 22 days after CAR-T reinfusion.
In 2024, the EBMT published the first comparison of four CAR-T treatments for RRMM in China and the US based on MAIC analysis.
Learn how BCMA CAR T-cell therapy can help improve prognosis for high-risk multiple myeloma.
Explore the 3 approved CAR-T therapies for multiple myeloma. Learn about their efficacy, patient experiences, and pricing, all in one place.
